Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis

被引：0

作者：

Steinman, Lawrence ^{[1
]}

Fox, Edward ^{[2
]}

Hartung, Hans-Peter ^{[3
]}

Cree, Bruce ^{[4
]}

Alvarez, Enrique ^{[5
]}

Qian, Peiqing ^{[6
]}

Wray, Sibyl ^{[7
]}

Robertson, Derrick ^{[8
]}

Huang, Deren ^{[9
]}

Selmaj, Krzystof ^{[10
]}

Wynn, Daniel ^{[11
]}

Weiss, Michael ^{[12
]}

Bosco, Jenna ^{[12
]}

Power, Sean ^{[12
]}

Mok, Koby ^{[12
]}

机构：

[1] Stanford Univ, Stanford, CA 94305 USA

[2] Cent Texas Neurol Consultants, Round Rock, TX USA

[3] Heinrich Heine Univ, Dusseldorf, Germany

[4] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA

[5] Univ Colorado, Boulder, CO 80309 USA

[6] Swedish Med Ctr, Englewood, CO 80110 USA

[7] Hope Neurol, Knoxville, TN USA

[8] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA

[9] Mt Carmel Neurol, Westerville, OH USA

[10] Med Acad Lodz, Lodz, Poland

[11] Consultants Neurol Ltd, Northbrook, IL USA

[12] TG Therapeut, New York, NY USA

来源：

NEUROLOGY | 2020年 / 94卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

4845

引用

页数：4

共 50 条

[1] A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Fox, Edward
Lovett-Racke, Amy E.
Gormley, Matthew
Liu, Yue
Petracca, Maria
Cocozza, Sirio
Shubin, Richard
Wray, Sibyl
Weiss, Michael S.
Bosco, Jenna A.
Power, Sean A.
Mok, Koby
Inglese, Matilde
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 420 - 429
[2] Study design and patient demographics of the ULTIMATE phase III trials evaluating Ublituximab (UTX), a novel glyco-engineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)
Steinman, L.
Fox, E.
Hartung, H. -P.
Alvarez, E.
Qian, P.
Wray, S.
Robertson, D.
Huang, D.
Selmaj, K.
Wynn, D.
Weiss, M.
Power, S.
Bosco, J.
Mok, K.
Cree, B.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 523 - 524
[3] 6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis
Fox, Edward J.
Lovett-Racke, Amy
Wray, Sibyl
Racke, Michael K.
Shubin, Richard
Twyman, Cary
Eubanks, James
Su, Wendy
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 23 - 23
[4] Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS).
Fox, E.
Lovett-Racke, A.
Gormley, M.
Liu, Y.
Wray, S.
Shubin, R.
Petracca, M.
Inglese, M.
Power, S.
Bosco, J.
Mok, K.
Weiss, M.
Eubanks, J.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 87 - 87
[5] Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Fox, Edward
Wray, Sibyl
Shubin, Richard
Bosco, Jenna
Weiss, Michael
Power, Sean
Mok, Koby
Eubanks, James
NEUROLOGY, 2019, 92 (15)
[6] Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis
Fox, E.
Steinman, L.
Hartung, H.
Alvarez, E.
Qian, P.
Wray, S.
Robertson, D.
Huang, D.
Selmaj, K.
Wynn, D.
Weiss, M. S.
Bosco, J. A.
Power, S. A.
Mok, K. A.
Lee, L.
Cree, B. A.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 68 - 68
[7] Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with RMS
Fox, Edward J.
Lovett-Racke, Amy
Gormley, Matthew
Liu, Yue
Petracca, Maria
Inglese, Matilde
Cocozza, Sirio
Wray, Sibyl
Shubin, Richard
Bosco, Jenna A.
Power, Sean A.
Weiss, Michael
Mok, Koby
Eubanks, James L.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 49 - 49
[8] Open Label Extension (OLE) of Phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with Relapsing forms of Multiple Sclerosis (RMS)
Fox, E.
Wray, S.
Shubin, R.
Mok, K.
Power, S.
Bosco, J.
Weiss, M.
Eubanks, J.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 105 - 105
[9] Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis
Fox, E.
Lovett-Racke, A.
Inglese, M.
Wray, S.
Racke, M.
Shubin, R.
Eubanks, J.
Su, W.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 407 - 407
[10] Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)
Fox, E.
Wray, S.
Shubin, R.
Lovett-Racke, A.
Huang, D.
Bass, A.
Weiss, M.
Power, S.
Bosco, J.
Mok, K.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 543 - 544

← 1 2 3 4 5 →